Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
Explore this paper's citation graph
Summary
Detailed sequence evaluation of exon 19 deletions may provide important prognostic information on survival outcome after TKI in patients with metastatic non–small-cell lung cancer harboring different subtypes of EGFR mutations.
- Type
- article
- Published
- 2013-09-01
- Cited by
- 123
- References
- 33
- Access
- Open access
- OpenAlex
- https://openalex.org/W23945384
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21055634
Keywords
Very-large-scale integration, Testability, Computer science, Design for testing, Automatic test pattern generation
References
- Next-generation sequencing for cancer diagnostics: a practical perspective.
- Detection of PCR products using self-probing amplicons and fluorescence
- Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
- Anticancer drugs: To the rescue?
- The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors
- Screening for epidermal growth factor receptor mutations in lung cancer.
- Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.
- Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
- Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
- Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
- Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
- Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
- Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
Cited by
- Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer
- Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
- [Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21].
- Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma.
- Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis
- Association of Merkel cell polyomavirus infection with EGFR mutation status in Chinese non-small cell lung cancer patients.
- Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
- Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case
- Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies.
- Epidermal growth factor receptor mutations in lung adenocarcinoma
- EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
- Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties
- MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data
- Racial diversity of actionable mutations in non-small cell lung cancer
- Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
- Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.
- Current and future molecular diagnostics in non-small-cell lung cancer
- Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Related papers
- VLSI Design for Testability
- VLSI testing and testability
- An Expert Solution to Functional Testability Analysis of VLSI Circuits
- Design for Testability of General Purpose VLSI
- Testability analysis based on structural and behavioral information
- A multilevel testability assistant for VLSI design
- A register-transfer level BIST partitioning approach for ASIC designs
- Testability Analysis of MOS VLSI Circuits